Neuroscientific Biopharmaceuticals Ltd has released a press release.
NSB - Company Update
Filed with ASX ·
On 6ix: 6ix.com/news/nsb-company-update
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- AGM Address
- EmtinB Can Become a Revolutionary Treatment for Glaucoma
- NSB Receives R&D Advanced Overseas Finding
- NSB - FInal Data Received from Spinal Cord Injury Model
- NSB - Breakthrough results from Spinal Cord Injury Model
Later from Neuroscientific Biopharmaceuticals
- CVN Model Indicates Neuroprotective Properties of EmtinB
- Additional US Patent granted
- Positive Results in Glaucoma Pig Model
- Positive Results in MS Study
- Final Report received for Glaucoma Study
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals